VAL-181388

Phase 1Completed
1 views this week 0 watching
0
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chikungunya Virus

Conditions

Chikungunya Virus

Trial Timeline

Jul 19, 2017 → Mar 19, 2019

About VAL-181388

VAL-181388 is a phase 1 stage product being developed by Moderna for Chikungunya Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT03325075. Target conditions include Chikungunya Virus.

What happened to similar drugs?

0 of 11 similar drugs in Chikungunya Virus were approved

Approved (0) Terminated (2) Active (9)
🔄CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3
🔄CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3
🔄CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3
🔄CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3
VLA1553Valneva SEPhase 3
🔄Biological Vaccine VLA1553Valneva SEPhase 3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03325075Phase 1Completed

Competing Products

20 competing products in Chikungunya Virus

See all competitors
ProductCompanyStageHype Score
mRNA-1944ModernaPhase 1
0
CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + PlaceboBavarian NordicPhase 2
32
ChikungunyaBavarian NordicPhase 2
32
CHIKV VLP vaccine booster + Placebo boosterBavarian NordicPhase 3
41
CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3
37
CHIKV VLP, adjuvantedBavarian NordicPhase 2
32
CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3
37
CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3
44
CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3
44
Live-attenuated CHIKV vaccine VLA1553Valneva SEPre-clinical
27
VLA1553Valneva SEPhase 3
26
Live-attenuated CHIKV vaccine VLA1553Valneva SEPre-clinical
24
Biological Vaccine VLA1553Valneva SEPhase 3
34
VLA1553 full dose + VLA1553 half dose + ControlValneva SEPhase 2
29
Active + PlaceboValneva SEPhase 3
34
Live-attenuated CHIKV vaccine VLA1553 + Vaccine(s) approved for use during pregnancy by the MoHValneva SEPre-clinical
27
VLA1553Valneva SEPhase 3
38
VLA1553 + ControlValneva SEPhase 3
26
VLA1553 + PlaceboValneva SEPhase 3
34
VLA1553Valneva SEPhase 1
23